A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors.
Tingting WangDangge WangHaijun YuBing FengFangyuan ZhouHanwu ZhangLei ZhouShi JiaoYaping LiPublished in: Nature communications (2018)
Vaccines to induce effective and sustained antitumor immunity have great potential for postoperative cancer therapy. However, a robust cancer vaccine simultaneously eliciting tumor-specific immunity and abolishing immune resistance continues to be a challenge. Here we present a personalized cancer vaccine (PVAX) for postsurgical immunotherapy. PVAX is developed by encapsulating JQ1 (a BRD4 inhibitor) and indocyanine green (ICG) co-loaded tumor cells with a hydrogel matrix. Activation of PVAX by 808 nm NIR laser irradiation significantly inhibits the tumor relapse by promoting the maturation of dendritic cells and eliciting tumor infiltration of cytotoxic T lymphocytes. A mechanical study reveals that NIR light-triggered antigen release and JQ1-mediated PD-L1 checkpoint blockade cumulatively contribute to the satisfied therapeutic effect. Furthermore, PVAX prepared from the autologous tumor cells induces patient-specific memory immune response to prevent tumor recurrence and metastasis. The PVAX model might provide novel insights for postoperative immunotherapy.
Keyphrases
- papillary thyroid
- immune response
- dendritic cells
- cancer therapy
- drug delivery
- patients undergoing
- photodynamic therapy
- squamous cell
- fluorescence imaging
- small cell lung cancer
- squamous cell carcinoma
- dna damage
- bone marrow
- drug release
- cell cycle
- oxidative stress
- wound healing
- mass spectrometry
- young adults
- climate change
- hyaluronic acid
- human health